Abstract
Immune mediated necrotizing myopathy (IMNM) is part of the inflammatory myopathies group of diseases and presents with muscle weakness, myalgias and elevated serum creatine phosphokinase (CPK). Statin-induced IMNM is a rare complication. We present a patient with IMNM secondary to simvastatin use. The patient presented with proximal myopathy, dysphagia, and elevated creatinine kinase levels, and was subsequently found to have anti-3- hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies with a necrotizing process on muscle biopsy. This patient’s case was further complicated by sequelae of multiple disease processes, ultimately leading to deterioration of his health.
Highlights
-c emerged as an immune mediated process, distinct from other idiopathic inflammatory n myopathies, such as dermatomyositis o (DM), polymyositis (PM) and inclusion N body myositis (IBM)
We report a case of anti-HMGCR dermatomyositis (DM), polymyositis (PM), weight loss.[1]
We report a case of anti-HMGCR positive m statin-induced immune mediated necrotizing myopathy (IMNM) resulting in death Non-com secondary to associated dysphagia
Summary
-c emerged as an immune mediated process, distinct from other idiopathic inflammatory n myopathies, such as dermatomyositis o (DM), polymyositis (PM) and inclusion N body myositis (IBM). Patients with statin-induced IMNM often present with progressive proximal muscle weakness and significantly elevated plication of statin use.[3] Prompt and accurate Immune mediated necrotizing myositis typically symmetric and lacks sensory cases patients have been on statin therapy (IMNM) is part of the inflammatory involvement.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call